跳至主要内容
临床试验/NCT00993850
NCT00993850已完成3 期

A Psychological Intervention for Individuals Who Suffer From Sleep Disturbance and Bipolar Disorder

University of California, Berkeley2 个研究点 分布在 1 个国家目标入组 52 人开始时间: 2009年10月最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
入组人数
52
试验地点
2
主要终点
Improvements in sleep, emotional functioning and quality of life

研究概览

简要总结

The study aims to evaluate a psychological intervention for individuals who suffer from sleep disturbance and bipolar disorder. We are hoping that this treatment will: (1) improve the quality of life of individuals with bipolar disorder who are suffering from sleep disturbance and (2) reduce the risk of, or help prevent, episodes.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Bipolar disorder patients with sleep disturbance
  • Meeting Diagnostic and Statistical Manual of Mental Disorders, 4th Text Revision (DSM-IV-TR; APA, 2000) diagnostic criteria for bipolar disorder type 1 (established with the SCID: Structured Clinical Interview for DSM-IV).
  • Being inter-episode throughout the experiment as defined by cutoffs widely used in previous research. On the basis that a drug-free group would likely be unfeasible and unrepresentative, participants will not be excluded on the basis of medications prescribed for bipolar disorder. Comorbidity will be allowed as long as bipolar disorder is the primary diagnosis. However, it is necessary to assess comorbidity for reporting purposes.
  • Participants who have a history of bipolar 1 or suicidal ideation must be under the care of a psychiatrist.
  • Experience distress related to significant sleep disturbance.

排除标准

  • Presence of an active and progressive physical illness (e.g., congestive heart failure, cancer, COPD) or neurological degenerative diseases (e.g., dementia, multiple sclerosis) directly related to the onset and course of insomnia;
  • Alcohol or drug abuse (except nicotine) within the past year
  • Active posttraumatic stress disorder
  • Evidence of sleep apnea, restless legs syndrome or periodic limb movements during sleep, or a circadian-based sleep disorder (e.g., delayed or advanced sleep phase syndrome)
  • Patients who pose a current suicidal risk or homicidal risk (assessed by treating psychiatrist) or who have made a suicide attempt within the past 6 months.
  • Pharmacotherapy for sleep defined as the benzodiazepine and non-benzodiazepine hypnotics that operate via the GABA A receptor complex and are FDA approved for the treatment of insomnia, selective melatonin agonists, benzodiazepine anxiolytics and over the counter medications with proven efficacy such as melatonin or herbs such as St. Johns wort.
  • Use of certain medications known to alter sleep (e.g., steroids, theophylline, propranolol, antihistamines that cause drowsiness).

结局指标

主要结局

Improvements in sleep, emotional functioning and quality of life

时间窗: 1 year

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Allison Harvey

Professor of Clinical Psychology

National Institute of Mental Health (NIMH)

研究点 (2)

Loading locations...

相似试验